Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

HL156A

 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

GuanidinesPyrrolidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Metabolic Reprogramming by the Excessive AMPK Activation Exacerbates Antigen-Specific Memory CD8+ T Cell Differentiation after Acute Lymphocytic Choriomeningitis Virus Infection
During virus infection, T cells must be adapted to activation and lineage differentiation states via metabolic reprogramming… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2018
2018
New metformin derivative HL156A prevents oral cancer progression by inhibiting the insulin‐like growth factor/AKT/mammalian target of rapamycin pathways
Metformin is a biguanide widely prescribed as an antidiabetic drug for type 2 diabetes mellitus patients. The purpose of the… Expand
2018
2018
Antioxidant modifications induced by the new metformin derivative HL156A regulate metabolic reprogramming in SAMP1/kl (-/-) mice
Aging is characterized by a reduced ability to defend against stress, an inability to maintain homeostasis, and an increased risk… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2018
2018
HL156A, a novel pharmacological agent with potent adenosine-monophosphate-activated protein kinase (AMPK) activator activity ameliorates renal fibrosis in a rat unilateral ureteral obstruction model
Background Renal fibrosis is characterized by excessive production and deposition of extracellular matrix (ECM), which leads to… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2016
2016
HL156A, a novel AMP-activated protein kinase activator, is protective against peritoneal fibrosis in an in vivo and in vitro model of peritoneal fibrosis.
HL156A is a novel AMP-activated protein kinase (AMPK) activator. We aimed to investigate the protective mechanism of HL156A… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2016
2016
Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A)
Studies have investigated biguanide-derived agents for the treatment of cancers and have reported their effects against… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2016
2016
AMP-activated protein kinase activator, HL156A reduces thioacetamide-induced liver fibrosis in mice and inhibits the activation of cultured hepatic stellate cells and macrophages.
Cirrhosis, the end-stage of hepatic fibrosis, is not only life-threatening by itself, but also a causative factor of liver cancer… Expand
2016
2016
AMP-activated protein kinase activator , HL 156 A reduces thioacetamide-induced liver fibrosis in mice and inhibits the activation of cultured hepatic stellate cells and macrophages
Cirrhosis, the end-stage of hepatic fibrosis, is not only life-threatening by itself, but also a causative factor of liver cancer… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2015
2015
HL 156 A , a novel AMP-activated protein kinase activator , is protective 3 against peritoneal fibrosis in an in-vivo and in-vitro model of peritoneal 4 fibrosis 5 6
45 HL156A is a novel adenosine5’-monophosphate-activated protein kinase (AMPK) activator. We 46 aimed to investigate the… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2008
2008
The AMPK activators, HL156A and HL176OUT04 reduce thioacetamide-induced hepatic fibrosis via the inhibition of hepatic stellate cell activation AMPK
.......................................................................1 LIST OF FIGURES… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE